Dyne Therapeutics, Inc. Expense Breakdown
No Expense Breakdown for DYN on this site yet.
- 2026-06-30: Dyne-251 (Dm1) $52.32M; Dyne-101 (Dm1) $48.98M.
- 2025-06-30: Dyne-251 (Dm1) $29.52M; Dyne-101 (Dm1) $34.68M.
Source checked: the stored Expense Breakdown page for DYN.
Expenses by product
Research and development: each quarter (3 month)
| Quarter end | Dyne-251 (Dm1) | Dyne-101 (Dm1) |
|---|---|---|
| 2026-06-30 | $52.32M | $48.98M |
| 2025-06-30 | $29.52M | $34.68M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |